Professional
Added to YB: 2024-04-22
Pitch date: 2024-04-08
ALNY [bullish]
Alnylam Pharmaceuticals, Inc.
+115.8%
current return
Author Info
No bio for this author
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Market Cap
$41.7B
Pitch Price
$157.26
Price Target
235.00 (-31%)
Dividend
N/A
EV/EBITDA
66.11
P/E
134.94
EV/Sales
11.24
Sector
Biotechnology
Category
special_situation
RBC Capital Markets Investment Thesis: Alnylam Pharmaceuticals, Inc.
ALNY: Confident in HELIOS-B TTR-CM trial despite CRL for Onpattro label expansion. Rich catalyst calendar: HELIOS-B topline in June/July, P2 KARDIA-2 hypertension combo data, P1 AD results. Fundamentally attractive with M&A optionality. $235 PT on DCF (10% WACC, 1% TGR). Risks: TTR-CM failure, competition, delayed profitability.
Read full article (2 min)